Upcoming events on BIONTECH SE |
|
08/07/23 | | Q2 2023 Earnings Release |
08/07/23 | 08:00am | | Q2 2023 Earnings Call |
11/06/23 | | Q3 2023 Earnings Release |
11/06/23 | 08:00am | | Q3 2023 Earnings Call |
11/07/23 | | Investor Meeting - Innovation Series |
03/26/24 | | Q4 2023 Earnings Release (Projected) |
05/06/24 | | Q1 2024 Earnings Release (Projected) |
08/05/24 | | Q2 2024 Earnings Release (Projected) |
11/04/24 | | Q3 2024 Earnings Release (Projected) |
|
Past events on BIONTECH SE |
|
06/02/23 | | American Society of Clinical Oncology Conference |
05/25/23 | 08:00am | | Annual General Meeting |
05/08/23 | 08:00am | | Q1 2023 Earnings Call |
05/08/23 | 06:45am | | Q1 2023 Earnings Release |
03/27/23 | 08:00am | | Q4 2022 Earnings Call |
03/27/23 | 06:45am | | Q4 2022 Earnings Release |
03/13/23 | 07:00am | | Oppenheimer Healthcare Conference |
01/10/23 | 12:45pm | | JP Morgan Healthcare Conference |
11/29/22 | | Evercore ISI HealthCONx Conference |
11/15/22 | 09:05am | | Jefferies London Healthcare Conference |
|
Past dividends on BIONTECH SE |
|
|
|
Fiscal Period : December | 2019 | 2020 | 2021 | 2022 | 2023 |
Sales M € |
Released Forecast Spread | 109 110 -1,6% | 482 432 12% | 18 977 17 212 10% | 17 311 16 583 4,4% | 5 655 |
Operating income (EBITDA) M € |
Released Forecast Spread | -148 -145 -1,9% | -43,7 -287 85% | 15 359 13 568 13% | 12 766 12 149 5,1% | 1 715 |
Operating profit (EBIT) M € |
Released Forecast Spread | -182 -167 -8,7% | -82,4 -306 73% | 15 284 13 364 14% | 12 643 12 016 5,2% | 1 450 |
Pre-Tax Profit (EBT) M € |
Released Forecast Spread | -179 -158 -14% | -146 -325 55% | 15 046 13 109 15% | 12 954 12 372 4,7% | 1 714 |
Net income M € |
Released Forecast Spread | -179 -157 -14% | 15,2 -336 105% | 10 293 9 140 13% | 9 434 8 838 6,7% | 1 361 |
EPS € |
Released Forecast Spread | -0,85 -0,74 -15% | 0,06 -1,44 104% | 39,6 36,2 9,4% | 37,8 35,2 7,4% | 5,22 | Announcement Date | 03/31/2020 | 03/30/2021 | 03/30/2022 | 03/27/2023 | - |
|
|
Fiscal Period : December | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 |
Sales M € |
Released Forecast Spread | 2 048 1 793 14% | 5 309 3 274 62% | 6 087 5 020 21% | 5 533 3 918 41% | 6 375 4 496 42% | 3 197 4 109 -22% | 3 461 1 903 82% | 4 278 3 863 11% | 1 277 1 092 17% | 616 | 1 657 | 2 190 | 861 | 614 |
Operating income (EBITDA) M € |
Released Forecast Spread | 1 675 1 385 21% | 4 215 2 528 67% | 4 743 3 000 58% | 4 726 2 750 72% |
|
| 2 421 1 184 104% | 3 322 3 297 0,76% | 686 -160 529% | -297 | 1 429 | 570 |
|
|
Operating profit (EBIT) M € |
Released Forecast Spread | 1 662 986 69% | 4 198 2 554 64% | 4 724 3 968 19% | 4 700 2 817 67% | 4 753 3 449 38% | 2 210 2 848 -22% | 2 388 1 295 84% | 3 293 2 543 29% | 654 226 189% | -52,6 | 442 | 511 | 79,6 | -337 |
Pre-Tax Profit (EBT) M € |
Released Forecast Spread | 1 642 1 379 19% | 4 023 2 637 53% | 4 667 3 309 41% | 4 714 2 475 90% | 5 018 3 337 50% | 2 319 2 892 -20% | 2 444 1 426 71% | 3 173 2 658 19% | 708 200 254% | 378 | 392 | 245 |
|
|
Net income M € |
Released Forecast Spread | 1 128 778 45% | 2 787 1 784 56% | 3 211 2 671 20% | 3 166 1 893 67% | 3 699 2 484 49% | 1 672 2 056 -19% | 1 785 930 92% | 2 279 1 931 18% | 502 110 358% | -64,9 | 512 | 619 |
|
|
EPS € |
Released Forecast Spread | 4,39 3,09 42% | 10,8 6,94 55% | 12,4 10,4 19% | 12,2 7,55 61% | 14,2 8,90 60% | 6,45 7,57 -15% | 6,98 4,86 43% | 9,26 8,07 15% | 2,05 0,57 258% | -0,51 | 1,53 | 2,72 | -0,35 | -1,00 | Announcement Date | 05/10/2021 | 08/09/2021 | 11/09/2021 | 03/30/2022 | 05/09/2022 | 08/08/2022 | 11/07/2022 | 03/27/2023 | 05/08/2023 | - | - | - | - | - | |
|
|
Upcoming sector events for BIONTECH SE |
|
|
|
Past sector events for BIONTECH SE |
|
|
|
|
|
|
Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancer |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|